Aileron Therapeutics (NASDAQ:ALRN) Posts Earnings Results, Misses Expectations By $0.20 EPS

Aileron Therapeutics (NASDAQ:ALRN) announced its quarterly earnings data on Wednesday. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.20), Zacks reports.

Aileron Therapeutics Stock Up 9.7 %

Shares of NASDAQ ALRN traded up $0.16 during trading hours on Friday, hitting $1.81. The company had a trading volume of 15,871 shares, compared to its average volume of 72,366. Aileron Therapeutics has a 1-year low of $1.01 and a 1-year high of $7.42. The firm’s 50 day moving average is $2.73 and its 200-day moving average is $4.06. The stock has a market capitalization of $39.12 million, a P/E ratio of -0.56 and a beta of 2.23.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Brookline Capital Management upgraded shares of Aileron Therapeutics to a “strong-buy” rating in a research note on Thursday, May 30th. LADENBURG THALM/SH SH lifted their target price on Aileron Therapeutics from $9.00 to $19.00 and gave the company a “buy” rating in a research report on Thursday, April 18th.

Insider Buying and Selling

In other Aileron Therapeutics news, major shareholder Of Texas/Texas Am I. University sold 9,342 shares of the stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $3.25, for a total value of $30,361.50. Following the completion of the sale, the insider now owns 1,753,156 shares in the company, valued at $5,697,757. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, major shareholder Of Texas/Texas Am I. University sold 9,577 shares of Aileron Therapeutics stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $3.30, for a total transaction of $31,604.10. Following the completion of the transaction, the insider now directly owns 1,768,250 shares in the company, valued at approximately $5,835,225. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Of Texas/Texas Am I. University sold 9,342 shares of the stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $3.25, for a total value of $30,361.50. Following the completion of the sale, the insider now owns 1,753,156 shares in the company, valued at approximately $5,697,757. The disclosure for this sale can be found here. Over the last three months, insiders have sold 33,557 shares of company stock worth $109,966. Insiders own 5.57% of the company’s stock.

About Aileron Therapeutics

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).